Compare FLO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLO | GLPG |
|---|---|---|
| Founded | 1919 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 704 |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2000 | N/A |
| Metric | FLO | GLPG |
|---|---|---|
| Price | $8.54 | $29.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $11.20 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 4.3M | 185.9K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $5,256,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.65 | N/A |
| P/E Ratio | $20.66 | ★ N/A |
| Revenue Growth | ★ 3.00 | N/A |
| 52 Week Low | $7.86 | $24.31 |
| 52 Week High | $18.53 | $37.78 |
| Indicator | FLO | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 39.44 |
| Support Level | N/A | $28.78 |
| Resistance Level | $8.62 | $34.04 |
| Average True Range (ATR) | 0.30 | 0.72 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 87.58 | 45.60 |
Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.